Simvastatin

The addition of simvastatin plus rifaximin to standard therapy did not improve outcomes among patients with decompensated cirrhosis who were at high risk for clinical complications, according to a study published in JAMA.

Simvastatin plus rifaximin did not reduce progression to acute-on-chronic liver failure, complications from cirrhosis or risk for death in patients with decompensated cirrhosis, according to data presented at EASL Congress.

Researchers observed no increased risk for new-onset diabetes among IMPROVE-IT participants assigned to ezetimibe plus statin therapy vs. statin monotherapy, according to a research letter.

Although lipid-lowering medications are generally well tolerated, rare complications can include statin-associated autoimmune myopathy and drug-induced acute pancreatitis, a speaker reported.

In a cohort of patients with type 2 diabetes treated with simvastatin, fenofibrate decreased the composite of heart failure hospitalizations or cardiovascular mortality, according to an analysis of the ACCORD Lipid trial.

High-risk patients with clinical atherosclerotic cardiovascular disease or multiple CV risk factors benefit from more intensive lipid-lowering therapy, and clinicians should initiate combination treatment sooner, according to a speaker.

Lipophilic statins appeared associated with reduced mortality among women with ovarian cancer, according to results of a retrospective study presented at American Association for Cancer Research Virtual Annual Meeting II.

PARIS — Patients with peripheral artery disease who maintained use of high-intensity statin therapy had significantly lower mortality than those who reduced the intensity of statin treatment or stopped taking statins, researchers reported.